[The effect of various methods of luteal phase supplementation on serum progesterone level].
OBJECTIVE
Examined was the effect of luteal phase supplementation on serum progesterone level with the use of two methods: oral administration of 10 mg dydrogesterone twice daily since the detection of corpus luteum till the menstruation and intramuscular HCG administration in the dose 1500 IU every 4 days and 10 mg dydrogesterone twice daily in the same period.


METHODS
A randomized study, controlled by placebo.


METHODS
56 infertile women, with luteal phase deficiency assessed on the basis of basal body temperature (decrease shortly after the peak the luteal phase shorter than 11 days) and ovulation determined sonographically. Progesterone was evaluated by an EIA method, on the 3rd, 7th and 11th day since the corpus luteum occurred.


RESULTS
The peak of progesterone concentration was assessed in the midluteal phase (7th day) in both supplemented groups, significantly higher than in the placebo group, also in group with dydrogesterone and HCG it was higher than in group with dydrogesterone alone. Progesterone concentration decrease on the 11th day after the ovulation to the values comparable with the placebo group.


CONCLUSIONS
It has been found that both methods increase serum progesterone level in the time of an assumed implantation but they do not affect the premenstrual period if conception is not achieved.
Jakiel
G
G
Kliniki Rozrodczości i Andrologii Akademii Medycznej w Lublinie.
Bokiniec
M
M
Bakalczuk
S
S
Jakubczak
A
A
Mroczkowski
A
A
D000328:Adult; D006063:Chorionic Gonadotropin / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004394:Dydrogesterone / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D008183:Luteal Phase / Q000187:drug effects*; D011374:Progesterone / Q000097:blood* / Q000378:metabolism*; D045167:Progesterone Congeners / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome
D006063:Chorionic Gonadotropin; D045167:Progesterone Congeners; D011374:Progesterone; D004394:Dydrogesterone